Actively Recruiting
Study of Tirzepatide to Improve Ovarian Function in Overweight or Obese Women with PCOS
Led by University of Bonn · Updated on 2026-01-08
198
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are investigating whether tirzepatide can improve ovarian dysfunction in premenopausal women with polycystic ovary syndrome PCOS who are overweight or have obesity. This phase IV, multi-center, randomized, double-blind, placebo-controlled trial aims to show that tirzepatide at the maximum tolerated dose is better than placebo for improving menstrual irregularity related to PCOS. The study is conducted at five sites in Germany and focuses on women aged 18 to 45 years with PCOS defined by specific criteria.
CONDITIONS
Brief Title
A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese
Research Team
W
Wiebke Fenske K. Head of Department at BG Universitätsklinikum Bochum, Professor
C
Charlotte Fries M. Senior Physician, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
